CIPLA Quality Chemical Industries Limited is a Uganda-based pharmaceutical manufacturing company. The Company's principal activity is manufacturing anti-retroviral drugs (ARVs) and Artemisinin-based Combination Therapies (ACTs) to combat human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and Malaria respectively. The Company also manufactures Hepatitis B medicines. The Company's products include anti-malarials, such as Lumartem; anti-retrovirals, such as Duovir-N, Duovir, Duomone, Efavir, Nevimune and Trioday, and Hepatitis B medicines, such as Texavir. Lumartem is a fixed dose ACT. Duovir-N is a fixed dose triple combination therapy used to treat HIV infection. Duomune is indicated in combination with at least one other antiretroviral medication for the treatment of HIV infection. Trioday is a triple fixed dose combination therapy used to treat HIV infection. Texavir is a montherapy of Tenofovir used to treat Hepatitis B.